Trimi vs PlushCare: Weight Loss Telehealth
Trimi and PlushCare represent two different approaches to GLP-1 weight loss treatment. Trimi is a specialized GLP-1 platform offering compounded medications at flat-rate pricing. PlushCare is a broad-spectrum telehealth platform that includes weight management among many services. This guide compares both options honestly so you can choose the right fit.
Transparency Note: This comparison is published by Trimi. We encourage you to verify all competitor information directly on PlushCare's website. Last verified: April 2026.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.
Quick Comparison
| Feature | Trimi | PlushCare |
|---|---|---|
| Primary focus | GLP-1 weight loss specialist | General telehealth (weight loss is one service) |
| GLP-1 medications | Compounded semaglutide, tirzepatide, retatrutide | Brand-name GLP-1 prescriptions (pharmacy fill) |
| Semaglutide pricing | $125/month (medication included) | Consultation fee + pharmacy cost (insurance dependent) |
| Tirzepatide pricing | $125/month (medication included) | Consultation fee + pharmacy cost (insurance dependent) |
| Insurance accepted | Cash-pay model | Yes, for consultations and some prescriptions |
| Medication included | Yes, in monthly price | No, prescription sent to pharmacy |
The Fundamental Difference
The core distinction between Trimi and PlushCare is their business model. Trimi is an all-inclusive GLP-1 program: you pay a monthly fee that covers the provider consultation, the medication, and shipping. PlushCare is a telehealth platform that provides consultations with doctors who can prescribe GLP-1 medications, but you fill the prescription at a separate pharmacy, typically through insurance or at retail cost.
This difference has significant implications for cost, convenience, and the overall treatment experience.
Medications and Access
Trimi
Trimi provides compounded semaglutide ($99/month), compounded tirzepatide ($125/month), and retatrutide directly to patients. Medications are sourced from FDA-registered 503B compounding pharmacies and shipped to your door. The all-inclusive model means no separate pharmacy visits, no insurance pre-authorization battles, and no surprise costs at the pharmacy counter.
PlushCare
PlushCare providers can prescribe brand-name GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. However, getting the prescription filled depends on your insurance coverage, pharmacy availability, and whether you can navigate the prior authorization process. Without insurance, brand-name GLP-1 medications can cost $1,000-1,500+ per month at retail pharmacy prices.
Where PlushCare excels: If you have insurance that covers brand-name GLP-1 medications, PlushCare can be an excellent pathway to getting a prescription. Their providers are experienced with insurance paperwork and prior authorizations. For patients with strong insurance coverage, the out-of-pocket cost through PlushCare may be very low. Additionally, PlushCare offers a broad range of medical services beyond weight loss, making it a versatile primary care platform.
Cost Analysis
The cost comparison depends entirely on your insurance situation:
If You Have Good Insurance Coverage
PlushCare may be more cost-effective. If your insurance covers Wegovy or Zepbound with a low copay ($25-50/month), combining a PlushCare consultation fee with your copay could be less than Trimi's monthly rate. This is the scenario where PlushCare has a genuine advantage.
If You Have No Insurance or Poor Coverage
Trimi is typically far more affordable. Without insurance coverage for brand-name GLP-1 medications, you would be looking at $1,000+ per month at a retail pharmacy versus $99/month through Trimi for compounded semaglutide. The math is straightforward in this case.
If Your Insurance Denies Coverage
Many patients discover their insurance does not cover weight loss medications or requires extensive prior authorization. In this common scenario, PlushCare can help you appeal, but there is no guarantee of approval. Meanwhile, Trimi provides immediate access to compounded medications without insurance involvement.
Provider Expertise
PlushCare employs board-certified physicians who handle a wide range of medical conditions, from weight loss to UTIs to mental health prescriptions. This breadth is valuable for general healthcare but means your weight loss provider may not specialize in GLP-1 therapy.
Trimi providers focus exclusively on GLP-1 weight management. This specialization means deeper familiarity with titration protocols, side effect management, medication switching strategies, and the nuances of optimizing GLP-1 treatment outcomes.
Who Each Program Is Best For
Choose Trimi If:
- You want an all-inclusive program with medication, provider, and shipping in one monthly fee
- You do not have insurance coverage for brand-name GLP-1 medications
- You want access to compounded semaglutide ($99/month) or tirzepatide ($125/month)
- You prefer a provider team that specializes in GLP-1 weight loss
- You want access to retatrutide as a treatment option
Choose PlushCare If:
- You have insurance that covers brand-name GLP-1 medications with a low copay
- You prefer brand-name medications (Wegovy, Ozempic, Zepbound, Mounjaro)
- You want a general telehealth platform that handles multiple health needs
- You are comfortable navigating insurance prior authorizations
- Your employer health plan specifically covers weight loss medications
What We Admire About PlushCare
PlushCare has built a strong general telehealth platform with high-quality providers. Their ability to work within the insurance system is genuinely valuable for patients who have coverage. They have also made primary care more accessible by reducing wait times and eliminating the need for in-person visits for many routine medical needs. Their model serves a different patient population than ours, and both approaches have merit.
Getting Started
If you have strong insurance coverage for GLP-1 medications, check with PlushCare about accessing brand-name options. If you want affordable, predictable pricing without insurance involvement, explore Trimi's treatment options starting at $99/month for compounded semaglutide and $125/month for compounded tirzepatide.
Frequently Asked Questions
Does PlushCare prescribe compounded semaglutide?
PlushCare primarily prescribes brand-name medications and sends prescriptions to retail pharmacies. If you want compounded semaglutide or tirzepatide at lower cost, Trimi provides these directly at $125/month and $125/month respectively.
Can PlushCare prescribe Wegovy or Zepbound?
Yes, PlushCare providers can prescribe brand-name GLP-1 medications. However, whether you can fill the prescription at an affordable cost depends on your insurance coverage and pharmacy availability. Brand-name GLP-1 medications remain subject to shortages and insurance restrictions.
Is Trimi cheaper than PlushCare for GLP-1?
For most patients without strong insurance coverage, yes. Trimi's $99/month semaglutide and $125/month tirzepatide are significantly less than brand-name medications at retail pharmacy prices. If you have insurance that covers GLP-1 medications with a low copay, PlushCare may be more cost-effective.
Can I switch from PlushCare to Trimi?
Yes. A Trimi provider will review your treatment history, current dose, and response, then continue or adjust your plan. Switching from brand-name to compounded medications of the same active ingredient is medically straightforward.
Does Trimi accept insurance?
Trimi operates on a cash-pay model with flat-rate pricing that includes medication, provider consultations, and shipping. This eliminates insurance complexity and keeps pricing predictable. Many patients find this more affordable than their insurance copay for brand-name GLP-1 medications.
More on GLP-1 Program Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).